Diagnosis and subclassification of the myeloid malignancies in moribund/deceased Tet2−/− and Tet2+/− mice up to 1 year of age
| Genotype . | Survival, d . | Frequency . | Necropsy and other findings . | Blasts*, % . | Transplantability . | Diagnosis and subclasification . |
|---|---|---|---|---|---|---|
| Tet2−/− | 92-196 | 12/21 | Hepatosplenomegaly anemia | < 20% | No | MDS with erythroid predominance |
| Tet2−/− | 208-298 | 4/21 | Hepatosplenomegaly monocytosis | < 20% | ND | CMML |
| Tet2−/− | 378-360 | 4/21 | Hepatosplenomegaly neutrophilia | < 20% | Yes | MPD-like Myeloid leukemia |
| Tet2−/− | 206 | 1/21 | Hepatosplenomegaly neutrophilia | > 20% | Yes | Myeloid leukemia with maturation |
| Tet2+/− | 316-365 | 2/5 | Hepatosplenomegaly neutrophilia (1 had myeloid sarcoma) | < 20% | Yes | MPD-like Myeloid leukemia |
| Tet2+/− | 238-365 | 3/5 | Splenomegaly monocytosis | < 20% | ND | CMML |
| Genotype . | Survival, d . | Frequency . | Necropsy and other findings . | Blasts*, % . | Transplantability . | Diagnosis and subclasification . |
|---|---|---|---|---|---|---|
| Tet2−/− | 92-196 | 12/21 | Hepatosplenomegaly anemia | < 20% | No | MDS with erythroid predominance |
| Tet2−/− | 208-298 | 4/21 | Hepatosplenomegaly monocytosis | < 20% | ND | CMML |
| Tet2−/− | 378-360 | 4/21 | Hepatosplenomegaly neutrophilia | < 20% | Yes | MPD-like Myeloid leukemia |
| Tet2−/− | 206 | 1/21 | Hepatosplenomegaly neutrophilia | > 20% | Yes | Myeloid leukemia with maturation |
| Tet2+/− | 316-365 | 2/5 | Hepatosplenomegaly neutrophilia (1 had myeloid sarcoma) | < 20% | Yes | MPD-like Myeloid leukemia |
| Tet2+/− | 238-365 | 3/5 | Splenomegaly monocytosis | < 20% | ND | CMML |
ND indicates not done.
Percentage of blasts in the BM.